News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
297,150 Results
Type
Article (23621)
Company Profile (59)
Press Release (273466)
Multimedia
Podcasts (30)
Webinars (15)
Section
Business (76408)
Career Advice (738)
Deals (11485)
Drug Delivery (57)
Drug Development (39910)
Employer Resources (71)
FDA (7168)
Job Trends (6519)
News (134990)
Policy (12622)
Tag
2027 Pharm Country Standard (1)
Academia (2160)
Accelerated approval (23)
Adcomms (19)
Allergies (72)
Alliances (23290)
ALS (132)
Alzheimer's disease (1319)
Antibody-drug conjugate (ADC) (147)
Approvals (7308)
Artificial intelligence (326)
Autoimmune disease (87)
Automation (20)
Bankruptcy (121)
Best Places to Work (5716)
BIOSECURE Act (15)
Biosimilars (74)
Biotechnology (39)
Bladder cancer (91)
Brain cancer (39)
Breast cancer (421)
Cancer (3054)
Cardiovascular disease (222)
Career advice (656)
Career pathing (20)
CAR-T (160)
CDC (28)
Celiac Disease (1)
Cell therapy (420)
Cervical cancer (25)
Clinical research (33821)
Collaboration (1040)
Company closure (2)
Compensation (159)
Complete response letters (38)
COVID-19 (1752)
CRISPR (54)
C-suite (465)
Cystic fibrosis (84)
Data (3900)
Decentralized trials (1)
Denatured (9)
Depression (85)
Diabetes (230)
Diagnostics (4048)
Digital health (18)
Diversity (6)
Diversity, equity & inclusion (23)
Drug discovery (149)
Drug pricing (78)
Drug shortages (6)
Duchenne muscular dystrophy (129)
Earnings (23840)
Editorial (37)
Employer branding (6)
Employer resources (64)
Events (40673)
Executive appointments (499)
FDA (9065)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (20)
Funding (972)
Gene editing (107)
Generative AI (23)
Gene therapy (396)
GLP-1 (375)
Government (2498)
Grass and pollen (2)
Guidances (182)
Healthcare (9185)
HIV (31)
Huntington's disease (33)
IgA nephropathy (72)
Immunology and inflammation (141)
Immuno-oncology (33)
Indications (61)
Infectious disease (1913)
Inflammatory bowel disease (119)
Inflation Reduction Act (7)
Influenza (73)
Intellectual property (138)
Interviews (106)
IPO (5472)
IRA (26)
Job creations (1002)
Job search strategy (559)
JPM (26)
Kidney cancer (10)
Labor market (35)
Layoffs (182)
Leadership (20)
Legal (1886)
Liver cancer (52)
Longevity (12)
Lung cancer (417)
Lymphoma (236)
Machine learning (24)
Management (24)
Manufacturing (424)
MASH (100)
Medical device (5448)
Medtech (5473)
Mergers & acquisitions (6523)
Metabolic disorders (596)
Multiple sclerosis (99)
NASH (8)
Neurodegenerative disease (245)
Neuropsychiatric disorders (55)
Neuroscience (2157)
Neurotech (1)
NextGen: Class of 2026 (3001)
Non-profit (3092)
Now hiring (10)
Obesity (247)
Opinion (184)
Ovarian cancer (85)
Pain (113)
Pancreatic cancer (133)
Parkinson's disease (207)
Partnered (22)
Patents (252)
Patient recruitment (326)
Peanut (28)
People (27337)
Pharmaceutical (16)
Pharmacy benefit managers (9)
Phase 1 (11040)
Phase 2 (15437)
Phase 3 (10773)
Pipeline (3033)
Policy (169)
Postmarket research (917)
Preclinical (4995)
Press Release (36)
Prostate cancer (156)
Psychedelics (39)
Radiopharmaceuticals (128)
Rare diseases (547)
Real estate (2131)
Recruiting (28)
Regulatory (10847)
Reports (23)
Research institute (2171)
Resumes & cover letters (94)
Rett syndrome (22)
RNA editing (9)
RSV (27)
Schizophrenia (92)
Series A (140)
Series B (109)
Service/supplier (1)
Sickle cell disease (66)
Special edition (5)
Spinal muscular atrophy (105)
Sponsored (34)
Startups (1759)
Stomach cancer (8)
Supply chain (48)
Tariffs (30)
The Weekly (20)
Vaccines (560)
Venture capital (49)
Weight loss (125)
Women's health (43)
Worklife (8)
Date
Last 7 days (315)
Last 30 days (1140)
Last 365 days (15902)
2026 (1521)
2025 (16102)
2024 (17498)
2023 (19697)
2022 (24538)
2021 (27152)
2020 (26274)
2019 (21551)
2018 (16025)
2017 (14302)
2016 (13532)
2015 (15566)
2014 (11120)
2013 (9091)
2012 (9441)
2011 (9667)
2010 (8115)
Location
Africa (346)
Alabama (72)
Alaska (3)
Arizona (132)
Arkansas (6)
Asia (17033)
Australia (3573)
California (5438)
Canada (1427)
China (544)
Colorado (235)
Connecticut (233)
Delaware (190)
Europe (38686)
Florida (925)
Georgia (169)
Hawaii (2)
Idaho (27)
Illinois (460)
India (38)
Indiana (208)
Iowa (14)
Japan (235)
Kansas (61)
Kentucky (25)
Louisiana (18)
Maine (28)
Maryland (701)
Massachusetts (4101)
Michigan (130)
Minnesota (244)
Mississippi (3)
Missouri (67)
Montana (17)
Nebraska (14)
Nevada (64)
New Hampshire (37)
New Jersey (1641)
New Mexico (22)
New York (1704)
North Carolina (630)
North Dakota (6)
Northern California (2569)
Ohio (203)
Oklahoma (17)
Oregon (20)
Pennsylvania (1080)
Puerto Rico (8)
Rhode Island (21)
South America (424)
South Carolina (21)
Southern California (2151)
Tennessee (106)
Texas (1112)
United States (20397)
Utah (219)
Vermont (1)
Virginia (141)
Washington D.C. (50)
Washington State (445)
West Virginia (3)
Wisconsin (68)
Wyoming (1)
297,150 Results for "critical path institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immuno-oncology
Replimune Crashes as Uncertainty Clouds Regulatory Path for Tumor Destroyer
Investors had been “holding out hope” that there remained a regulatory path forward for RP1, but results of Replimune’s Type A meeting with the FDA do not appear to support this, according to BMO Capital Markets.
September 19, 2025
·
2 min read
·
Tristan Manalac
Opinion
For Scalable Success in Cell Therapy, Regional Manufacturing Is the Smart Middle Path
The patient-specific nature of autologous cell therapies presents unique challenges that can best be addressed by a middle path between on-site and centralized manufacturing.
September 16, 2025
·
5 min read
·
Jane Koo
Press Releases
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
January 23, 2026
·
4 min read
Press Releases
Renew Biotechnologies Advances Epigenetic Diagnostics Through Launch of Path Fertility’s NOA Guide
January 30, 2026
·
2 min read
Press Releases
4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer
January 23, 2026
·
4 min read
Immunology and inflammation
Priovant Plots Path to Phase 3 as Brepocitinib Clears Mid-Stage Skin Disease Study
According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.
February 6, 2026
·
2 min read
·
Tristan Manalac
Business
JPM26: Lilly Plots Path to Dominance as Obesity Market Enters a New Era
BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient access improves.
January 14, 2026
·
2 min read
·
Nick Paul Taylor
Pain
Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill
The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid painkillers, Jefferies analysts suggested.
January 22, 2026
·
2 min read
·
Tristan Manalac
Weight Loss
Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones
The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with their new obesity pills this year.
January 5, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
Nxera Announces Focused Restructuring to Enhance Path to Profitability
November 17, 2025
·
8 min read
1 of 29,715
Next
